This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk25: Good day, and thank you for standing by. Welcome to the Akoya Biosciences first quarter 2023 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand it over to our first speaker.
spk26: Thank you, Operator, and thank you to everyone who is joining us today on this call. I'm Priyam Shah, Head of Investor Relations at Akoya Biosciences. On the call today, we have Brian McElligan, Chief Executive Officer, and Johnny Yak, our newly appointed Chief Financial Officer. Earlier today, ACOIA released financial results for the first quarter and did March 31st, 2023. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. For a list and description of the risks and uncertainties associated with the COIS business, please refer to the risks identified in our filings with the U.S. Securities and Exchange Commission, including in the risk factors section of our annual report on Form 10-K for the year ended December 31, 2022, filed on March 6, 2023, and subsequent filings of the SEC, including our quarterly report on Form 10-Q for the quarter ended March 31, 2023, filed today, May 8, 2023. We urge you to consider these factors, and you should be aware that these statements are considered estimates only and are not a guarantee of future performance. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, May 8th, 2023. ACOIA disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. The audio portion of this call will be archived on the investor section of our website later today under the heading events. And with that, I will now turn the call over to Brian.
spk16: Thank you, Prem, and good afternoon or evening to everyone. We appreciate you joining us today. On today's call, we will discuss our performance for the first quarter, review our product strategy, and give updates on the upcoming product launches. Johnny will then provide a more detailed look at our financials, business trends, and outlook. I'd like to start by extending a warm welcome to Johnny Eck, who joined Acquia's leadership team as Chief Financial Officer in March. Johnny brings more than 20 years of financial and operational leadership across the diagnostics and life sciences industries, including at leading companies like Affymetrix, Genmark, and most recently, Specific Diagnostics. Johnny succeeds Joe Driscoll following his retirement. Joe was an integral part of Acquia's success over the last four years. and guided the company through an incredible growth trajectory, including our IPO. He will be missed, and I wish him a wonderful and well-deserved retirement. Additionally, we announced the appointment of Jennifer Comichai as our new general counsel. She will be a vital member of the executive leadership team and will oversee all the company legal activities. So let me move on briefly to summarize our performance in Q1. Akoya had a very strong start to 2023, highlighted by the placement of our 1000th instrument in the field in April. This was a major milestone for the company. We also reported record revenue of $21.4 million for the first quarter, a 27% growth over the prior year. Our continued robust growth is a byproduct of our leadership in spatial biology, delivering a portfolio of products and services spans the full continuum of market opportunities from early discovery to translational and ultimately the clinical markets. Now, this is an important and valuable differentiator for Akoya. That is, we're achieving success across a broad range of market segments with complete end-to-end solutions purpose-built to serve the unique needs of each customer type. This range and diversity of products provides the company with a strong foundation and the core fundamentals for both near-term and long-term sustained growth. A key demonstration of our current and predictor of our ongoing success is the continued and rapid growth of publications featuring ACOIA's platforms. As of March 31st, there are now 860 publications featuring our solutions, a 62% growth from the prior year period. Additional highlights for the quarter include $5.7 million in reagent revenue, a 27% sequential quarter-over-quarter growth, and the largest quarterly reagent revenue in ACOIA's history. We reported $5.9 million in service and other revenue, a 64% year-over-year growth driven by the continued success of our lab services business. Prior to reviewing our forthcoming strategic initiatives, I want to spend a minute to review and reiterate ACOYA's multi-year strategy initiated following our IPO in April of 2021. Our primary goal was to establish ACOYA as the market leader in spatial biology from discovery to diagnostics. Now, there's two phases to this strategy. The first phase was initiated following the IPO and lasted to the end of 2022 and included three distinct strategic objectives. First, following the IPO, we made immediate investments in R&D to develop and deliver a complete and industry-leading portfolio of instruments and solutions to serve the discovery, translational, and clinical markets. We expanded our SG&A organization to have the scale, the expertise, the processes, and the systems in place to immediately capitalize on these product launches to drive revenue growth. Third, we solidified the clinical readiness of our organization and our product portfolio to set the foundations to achieve our long-term goal of penetrating the large spatial biology clinical camp. And by all accounts, We successfully executed on this the first phase of our strategy. Specifically, we delivered solid revenue growth ahead of expectations every quarter since our IPO in April of 2021 through Q1 of this year. We successfully launched new products like Diffusion as key drivers of this growth. And we launched and expanded our lab services business and achieved CLIA certification culminating in our first companion diagnostic partnership. Our revenue performance, 1,000 instruments in the field, and nearly 900 publications are the most obvious metrics that highlight our solid R&D and commercial execution. And now in 2023, we are embarking on the second phase of this multi-year strategy to lead in spatial biology from discovery to diagnostic. And now underway, the objectives of this second phase include the following. First, with our organization now at a scale to deliver on our strategic priorities, we will focus on improving operational leverage by limiting and targeting our investments while also continuing to deliver robust top-line growth. Second, we're focusing our R&D initiatives on workflow improvements and reagent solutions that drive increases in consumable revenue and system pull-through. Over time, we expect that these high margin reagents will contribute a growing percentage of our total overall revenue, driving an increase in our gross margins. Third, we will continue to focus on advancing our clinical market development efforts, lab services, and advancing and expanding key partnerships like Akron and Agilent to begin to address the significant spatial clinical opportunity. The goal of this second phase of our strategy will be to deliver sustained high top-line growth with increasing margins, achieve cash flow positivity in 2025, and to expand on our success in the clinical market. So now let me walk through our product roadmap for this year with the goal of continued workflow simplification and consumable revenue growth. We have coordinated priorities for investments and improvements across reagents, instruments, and software. We expect that our expanded reagent menu with our PhenoCode discovery and signature panels will drive an increase in system utilization, Plex, and pull-through. Our planned hardware upgrades on both the PhenoCycler Fusion and the HT will further simplify our workflows and also contributing to utilization and pull-through growth. And our expanding ecosystem of software partners will reduce our customers' time from data to answer. Let me talk in more detail in each of these, first starting with our reagent strategy. We are expanding our reagent menu this year with ready-made panels for both the phenocyclic diffusion for HyFlex Discovery and the PhenoImager HT for high-throughput translational studies. These biomarker panels fall under our PhenoCode reagent brand and include our PhenoCode discovery panels for the phenocycler fusion and the PhenoCode signature panels for the PhenoImager HT. The discovery panels will have a rolling launch throughout 2023. The first panel focused on immune profiling was launched at this year's AACR. The next three panels were launched throughout the second half of this year. These panels are designed in a modular fashion of 10 to 20 markers, providing our customers the ability to combine them while also including additional ACOIA catalog antibodies or their own as needed. For the translational clinical markets, we're launching five PhenoCode signature panels for the PhenoImager HT. The first three panels were launched in Q1, and the next two are due in the second half of this year. These panels were created for the rapidly advancing immuno-oncology therapy landscape that includes nearly 6,000 ongoing clinical trials. The signature panels enable fast and scalable assay to development and deployment, and accelerating utilization and higher revenue per sample on our HT system. With the launch of these high-value reagent panels, we're also making continued workflow improvements across all of our systems to simplify and accelerate our workflows. As previously discussed, the Fusion 2.0 instrument field upgrade is planned for this the second quarter and will deliver an increase in throughput and workflow simplification for our customers. This upgrade includes a multi-slide carrier on the fusion for parallel processing of tissue samples, which effectively doubles the system throughput from approximately 10 samples per week to up to 20 or more samples per week. This upgrade also includes the necessary hardware and software components to support biotechnics R&A scope to be used on the phenocyclofusion. On the PhenoImager HT, we are continuing our efforts to simplify and streamline our informatic workflow and post-processing to a true clinical standard. In mid-2023, we plan to introduce further improvements to the HT that moves the post-processing and tissue analysis steps directly onto the HT for on-instrument real-time compute. The result will be a several-fold reduction in image post-processing and turnaround time. This upgrade supports our translational and clinical customers' demand for a rapid and standardized workflow to drive throughput and standardization. Expanding our content menu and streamlining our workflows are two out of the three necessary improvements to drive increased system use. continue to advance and improve our data analysis and software solutions is the final piece. As we have discussed, our software strategy is grounded in two assumptions that are absolutely proving true. First, the rapidly expanding spatial biology market is driving the introduction of many new powerful data analysis solutions from both industry and academia. Our customers benefit the most if we can partner with these groups to ensure compatibility with our platforms. Second, our resources are better spent enabling these partners versus building a single solution that must serve this broad range of customer needs. And to remind you, Akoya's platforms leverage an on-instrument image processing and file compression technology that reduces file sizes by 30-fold. from terabytes to gigabytes, into a standardized file format called QPTIF. Now, this novel and proprietary technology enables an ease of data transfer through this standardized format to help simplify and accelerate the development of third-party software solutions. At ACR, we announced the newest member of a software partner ecosystem, EnableMedicine. Enable is now commercializing a cloud platform specifically optimized for phenocycler data sets. To date, they have already established the platform's robustness, having analyzed over 20,000 samples on the Enable cloud platform. Available as a software as a solution package, it will accelerate the ability of Akoya's customers to go from data to cell phenotypes to insights in minutes or hours instead of days or weeks. In addition to this partnership, we have also partnered with other established industry leaders like Visioform, Indica Labs, Path AI, and Oracle Bio. We expect the continued growth of spatial biology will spur ongoing developments of additional software solutions for the discovery, translation, and clinical markets. In addition to the upstream discovery market, we continue to make great progress in the downstream translational and clinical diagnostic markets, leveraging the PhenoImager HT and our Advanced Biopharmaceutical Solutions CLIA Lab or ABS. Our partnership with Angeline has already generated meaningful customer engagements with top biopharmaceutical precision medicine groups, driving and expanding our ABS pipeline. In addition, Our agreement with Akravan Therapeutics to exclusively co-develop and commercialize a first-of-its-kind spatial signature companion diagnostics continues to advance. Akravan recently announced that it anticipates initial clinical data from the Phase II multicenter open-label trial in patients with platinum-resistant ovarian, endometrial, and urothelial cancer during the second half of 2023. Now, to review, we're focused on the following initiatives throughout the rest of 2023. First, continue to deliver new applications and drive further workflow and speed improvements to increase the reagent pull-through on the phenocycler fusion in the discovery market and the PhenoImager HT for the translational and clinical markets. Second, continue to partner with leading biopharma, medical centers, CROs, and diagnostic leaders to drive the adoption of the PhenoImager HD in the translational research and clinical diagnostic markets. Finally, with the support of our new and expanded leadership team, we will drive operational efficiencies and make limited and targeted investments going forward to achieve cash flow positivity in 2025. Now, with that, I will now turn the call over to Johnny to discuss our financial results. Johnny?
spk09: Thanks, Brian, for the kind introduction and warm welcome. It's a pleasure to be on this call today, and I look forward to working alongside Brian and the team in leading Akoya on the next phase of its journey. And I want to thank Joe for what has been a seamless transition, and I wish him all the best in his retirement. As Brian highlighted, total revenue for the first quarter of 2023 was $21.4 million. a 27% growth over the first quarter of 2022. Our robust year-over-year growth reflects a strong portfolio meeting the needs of a broad customer base across multiple research verticals and revenue categories. Product revenue, including instruments, reagents, and software, totaled $15.5 million for the first quarter, representing 17% growth over the prior year period. Instrument revenue was $9.6 million for the first quarter, representing 13% growth over the prior year period. We had another strong quarter with 58 total instruments sold, of which 19 were phenocyclers and 39 were from the PhenoImager portfolio. We ended the first quarter of 2023 with a total installed base of 992 instruments, which includes 273 phenocyclers and 719 phenol imagers. As Brian highlighted, in April, we celebrated an important milestone, shipping our 1,000th instrument. A total of 149 fusion instruments have shipped since the full commercial launch at the start of 2022, and we now have a total install base of 128 for the combined phenocycler fusion system sold either directly as a combined system or as an upgrade to a standalone phenocycler instrument that previously utilized a third-party microscope. More than a year into the launch, the majority of the phenocyclers are being sold in combination with the fusion. As expected, we see the combination of the phenocycler and fusion driving increased reagent pull-through, and we expect this to continue to increase over the coming years with new product introductions, which Brian discussed as part of our product roadmap. Reagent revenue was $5.7 million for the first quarter of 2023, representing a 27% sequential growth over the fourth quarter of 2022. In this early part of 2023, we are seeing the efforts of our focus on driving reagent growth begin to show encouraging results. Our annualized pull-through per instrument in 2022 was in the low $30,000 range for both the phenocycler which was predominantly paired with third-party microscopes, and the phenol imager HT. The annualized first-quarter reagent pull-through was in the mid-$30,000 range as more phenocyclers paired with fusion are up and running. We are targeting annual reagent revenue growth in the 40% range per year for the next several years as we expand our install base, realize pull-through expansion across this large install base, and as ongoing product launches hit a commercial stride. Service and other revenue totaled $5.9 million for the first quarter, an increase of 64% over the prior year period. Services have been a substantial growth segment for us over the past several quarters for a couple of reasons. Lab services revenue continues to grow as more pharma customers utilize our services to drive higher scale studies and our companion diagnostic deal with Akron Therapeutics continues to advance with the clinical trial underway. Gross profit was $12.3 million in the first quarter, representing 22% year-on-year growth, and gross margin was 57.4%, an increase from 56.8% in Q4 of 2022. As reagents become a bigger part of our revenue mix, And as we leverage our manufacturing investments to date, we will continue to expand our gross margin over time. Operating expenses for the quarter totaled $29.9 million as compared to $29.6 million in the fourth quarter of 2022. As Brian noted, we have now begun to leverage our cost structure to drive the business towards profitability and are planning a flattening of our operating spend throughout 2023 and into 2024. With historical investments in business expansion efforts since the IPO, we have developed products, built operating infrastructure, and streamlined commercial execution to drive top line growth with expanding operating leverage. Our plan for 2023 includes targeted investments in areas that will generate the highest returns as we work towards operating cash flow positivity in 2025. We ended the quarter with approximately $60 million of cash and cash equivalents and approximately $11 million in additional debt capacity. The first quarter of each fiscal year is typically our highest cash usage quarter as we make bonus and other similar annual payments. In addition, we have invested in higher inventory levels to continue to cushion against potential supply chain issues and offer a more expansive reagent menu. We expect to maintain robust top-line growth throughout 2023 with reduced cash burn as we recognize operating leverage and flattened op-ex. Common shares outstanding and fully diluted shares, including the impact of outstanding options and unvested restricted stock awards, are 38.4 million as of March 31st, 2023. To summarize, We had another record quarter with $21.4 million in revenue, 27% growth over the prior year. We had a total installed base of 1,000 instruments as of April, the largest installed base in the spatial biology industry. We reported our highest reagent revenue in ACOIA's history this quarter of $5.7 million, representing 27% sequential quarter-over-quarter growth driven by an expanding installed base and increasing pull-through on the phenocycler fusion. And finally, with an industry-leading volume of publication featuring ACOIA's platforms, now at 860 as of quarter end, representing a 62% year-over-year increase, we remain confident in our ability to deliver continued growth in 2023. Currently, we are reiterating our revenue guidance range of $95 to $98 million for 2023 as we continue to see tailwinds for our business and the spatial biology market. Now, I'll turn it back over to Brian for closing remarks.
spk16: Thank you, Johnny. We're pleased to report a strong quarter and announce multiple exciting new developments across the portfolio. We're thankful for the hard work of our fellow dedicated Akoyans, as well as for the support of our customers and shareholders. Akoya remains very well positioned for growth and we're excited about the opportunities that lie ahead as we deliver new spatial solutions from the discovery to the clinical markets. And at this point, we will turn the call over to the operator for questions.
spk25: Thank you. At this time, we will conduct a question and answer session. As a reminder to ask a question, you will need to press star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press star 11 again
spk24: Please stand by while we compile the Q&A roster. Our first question comes from Tim Chang from Capital One.
spk25: Your line is now open.
spk02: Hey, thanks. Hey, Brian, you know, I listened to the Acrovan Therapeutics call that happened recently. You know, do you guys get significant milestone payments assuming that their clinical readouts in phase two, let's assume they are positive, would you guys get milestones from that?
spk16: We do. We get milestones without going into too much details, but we get milestones throughout the development phases and throughout the enrollment and clinical trial participation phases. as well as the readout on those. So it's a fairly typical, Tim, companion diagnostic agreement, but short answer is yes.
spk02: And maybe just a follow-up to that. I mean, obviously, there's a lot of precision medicine biotech companies out there. Yeah. You know, what do you think you need to do to get more of these types of deals where you can leverage your diagnostic capabilities on the clinical side?
spk16: Yeah, and maybe that's a great question, Tim, and I appreciate it. Maybe for the benefit of those that don't have the background, I maybe just back up a little bit. So we announced the partnership with Akraban last summer following their IND submission of their DNA damage repair compound, their phase two trial of the compound they in-licensed from Lilly. And that trial, that IND also included the CDX assay that was run on our platform. And it's being run out of our CLIA lab. So the things that we need to accomplish, to your question directly, Tim, to secure more of these, is really, as we've spoken of prior, is really to continue, I'd say, shots on goal. It's opportunities in more and more clinical trials In a more more clinical trials within our existing customer base and across multiple partners to increase the probability Like we have with Akravan where it becomes central to the actual clinical trial And while we don't call out all of these details Specifically as a separate line item. I think if you just look at our services line over the last five quarters or so of That's a pretty solid indication of us growing that business, but trying to be selective about it as well, Tim. And the milestones for us to continue to march along, the CLIA lab was certainly an important milestone. This first companion diagnostic deal is a very important milestone because it gives our pharma partners the confidence and belief that we can handle the whole submission process and end up having an improved system on market. And then finally, more recently, it's in January, the partnership with Agilent that provides our pharma partners the ability to have a full sort of clinical grade workflow and a partner between us and Agilent to know how to develop, run clinical studies and commercially deploy a clinical trial. So there's a lot that goes into it, Tim, but it really is just a sort of a slow, steady grind to broaden the menu and number of opportunities we have within our clinical trial partner base.
spk02: Okay, great. No, that's very helpful, Brian. And, you know, best of luck getting more of these types of partnerships this year. Thank you.
spk25: Thank you. One moment as I prepare the queue for our next question.
spk24: Our next question comes from Mason Curricio of Stevens, Inc.
spk25: Your line is now open.
spk08: Hey, guys. Thanks for taking the questions. Sorry if I missed this. I'm jumping between a few calls here. But did you guys discuss revenue and growth by geography during the quarter? And if not, could you provide some color there?
spk16: Yeah, it's a good question. We did not. It was fairly balanced across all territories and across all product lines. There was no real outliers. Last year, there was some puts and takes across multiple categories that It wasn't relegated to us. But for us, it was fairly balanced across all categories. You know, China's starting to come back a little bit on the reagent side, not fully there. But all in all, there was no sort of real outliers.
spk08: Okay. Got it. Thanks. That's helpful. And then one more here on performance. I think when you guys were talking about the pull-through per instrument, you called out a range in the mid-40s over the next couple years. Yeah. Has that changed from any prior expectations, maybe any additional color there? I know that new platform owners tend to have lower pull-through initially. So has your expectations changed around instrument placements? Has it gone up? Any additional detail there would be helpful.
spk16: No changes in instrument expectations or longer-term pull-through expectations. You know, we are beginning to realize, as Johnny alluded to in his talk track, we're starting to see the movement of that pull through on the phenocycler with many of those, you know, first half phenocycler infusion installs getting to full production. So, kind of going from the low 30s to mid 30s. And I think Mason will continue, particularly on the phenocycler, will continue to see this sort of steady climb. I'll pull through. You know, the overall reagent revenue of $5.7 million for this quarter was a pretty good step up from the 4.5 in Q4 last year. So no real increase in expectations. And I think everything that we're doing on the product side is going to help drive that, as I alluded to in my opening comments.
spk08: Perfect. Okay. And then one more maybe high-level question. I think historically you guys have talked about somewhat of a bifurcation in the spatial market or discovery market. Protein labs, where you guys have historically focused, and then some genomic labs where competitors tend to play. But you've also pointed to this trend of multiomics and the expectation that the market is moving in that direction. So with that in mind, when you think about the protein versus genomics labs, how do you think about which type of lab is is going to more rapidly adopt multi-omic solutions as these roll out or even use the analyte that they historically weren't broadly using in their research, whether it's RNA or protein?
spk16: Yeah, that's a great, great question. I'm going to rephrase it, Mason, to make sure I'm answering it correctly, which is you talked about proteomics and genomics customers. Where do we think multi-omics is going to resonate the most? To rephrase it simply, is that what you're asking? Yep, that's right. I actually think it's going to be more in the phenocycler fusion customer base because what they're looking at are they're looking at proteins as a really rich scaffold within which to understand cell-cell interactions as well as the key protein markers like the PD-1, PD-A1 checkpoints. And they're layering in RNA as an additive tool to look at secreted molecules and Chemokines, cytokines is an added question. So I think that kind of multi-omic customer is where your classic, you know, protein player is going to resonate the most. I think over time, I think you're going to see the genomics customers continue to focus more and more on genomics-based open-ended exploratory discovery questions, and that's the power of the transcript. So hopefully that answers your question. I think we're in that multiomics short story. Perfect. Yeah. Thanks, guys. Thanks, Mason.
spk25: Thank you.
spk24: One moment as I prepare our next question. Our next question comes from Julia Quinn of JP Morgan.
spk25: Your line is now open.
spk20: Hi, good afternoon, guys. So I wanted to ask on the service revenue strength this quarter, could you give us a little more color on, you know, whether this is mainly driven by Akron scaling their studies or new biopharma customers? And then also two related follow-ups on that is, you know, are you seeing any changes in customer preference between service versus instrument, just in light of the macro environment we're in? And could you talk about the biopharma pipeline health and what's your latest outlook for the service business, given the strength? Thank you.
spk16: Yeah, so the growth in services is sort of a balanced contribution. Appreciate the question, Julia. A balanced contribution over the last five quarters or so from both of those sources. That is, both the AcroVom milestones and realizing revenue recognizing that as well as the growth in ABS now there is a component of that that also includes warranties and those that those sort of grow linearly with our install base and that's a component of that it's probably a minority that is and your second part of your question are we seeing preferences for services versus buying instrumentation there's nothing Julia I would point to that would significant that would signify a massive shift within how we go to the market with one very important asterisk which is we are seeing a lot more activity within our CEOs and core labs so it's not services by Akoya because the services that we're doing with ABS and Acrobon those are very targeted and that's a pretty rich pipeline of targeted translational clinical studies but more generally Julia I do think you're seeing in the external markets people shifting, and Able Medicine is one of those CROs that also has software. You know, core labs at many of our academic institutions. You're seeing these cores be a very, a really central component of not only how products go to market, but the first wave of adoption. That's one of the reasons why we think it's so important on the discovery side to focus on that throughput, that sample per unit time. Because then these core labs can actually have a business. If it's a sample every three to four days, they're going to have to charge a markup of thousands and thousands of dollars per sample. That's why throughput is so important on the discovery side. And then on the translational side, it's equally important to make sure that we have panels that are ready to go and are pre-automated so that these CROs can go out and market a full solution and not have to build panels anymore. So the service portion of the business that we're serving versus providing, I actually do think there's a trend towards that. It's a very important customer base. And then the biopharma pipeline, I think there's two ways to talk about it. As we look at our top pull-through accounts over the last few quarters, for both the phenocycler fusion as well as the HT, BioPharma are becoming an increasing percentage of those really high-performing accounts. So we're really seeing our platforms take off in BioPharma as a product sale, but also our BioPharma business, in terms of ABS that I already spoke to, that is pretty robust. But again, it's very targeted. So hopefully that answers your question, Julia.
spk20: Thank you very much.
spk16: Thank you.
spk24: Thank you. One moment as I prepare our next question. Our next question comes from Mark Massario of BTIG.
spk25: Your line is now open.
spk22: Hey, guys. This is Vivian on for Mark. Thanks for taking the question. So could you update us on what the attachment rate for the genocycler fusion is for new customers as well as the existing installed base? I think it was hovering around 80% last quarter. And is it still your thinking that standalone phenocyclers will be in the minority going forward?
spk16: Thanks. Your numbers are correct, and so are your assumptions. And Johnny can correct me. But yeah, our attachment rate is above 80%. We think it's going to stay there. And there is still a... there's still a great opportunity for us to continue to upgrade existing phenocycler customers that are using third-party scopes. And as we roll out more and more product improvements to the phenocycler fusion, it's going to become sort of a growing attraction for those phenocycler customers to then upgrade to the fusion. Did that answer your question, Vivian?
spk22: Yes, perfect. Thanks, Brian. Thanks. Just a follow-up, any preliminary thoughts on how the field upgrades for the Fusion 2.0 are progressing? And any initial feedback you've been receiving on the 2.0, I guess, in terms of the increase in throughput?
spk16: Yeah, those start next month. Okay. Yeah, so there's a lot of excitement and anticipation for those. Those will be rolling out next month. And, you know, the pace of those is sort of customer-dependent. in terms of are they mid-project, do they have to wait? So I don't think we're giving exact guidance on how many quarters it's going to take, but we expect that there'll be a lot of excitement for that upgrade because of the improvements, not just on the hardware side, the multi-slide carrier, but there's also some significant improvements on the software side in terms of workflow usability.
spk21: Okay, awesome. That's it for me. Thanks for taking the question.
spk24: Thank you. Thank you. One moment as I prepare for the next question. Our next question comes from Kyle Mixon of Canaccord Genuinity.
spk25: Your line is now open.
spk07: Hey guys, thanks for taking the questions. Congrats on the quarter and thanks for providing the second phase strategic objectives. Those were actually pretty helpful. I think there are important components here that you kind of walk through the roadmap and so forth. But on the cash flow positivity by 2025, I just want to walk through some stuff there. So really, how do you get there? I think I heard you guys talking about it. I think, John, you went into it in some detail. R&D efficiency is limited in targeted spending. Maybe you could just expand on it a little bit. I mean, it was good to hear that stuff. And then maybe the assumption is just P&L-wise, so flattening off X, top-line growth, things like that. And importantly, if you guys could just talk through if you're contemplating any additional financing, because based on the burn here, I mean, it kind of seems possible. So I just sort of appreciate that. Thanks.
spk09: Yeah, I'll take this one. Certainly. Hey, Kyle, thank you. So maybe it's helpful to kind of give building blocks. Right. We think about, as you mentioned, we exit the quarter 60 million change with 11 million in change as additional debt capacity. So starting the quarter with 70 million. in capacity. And then we look at what we're going to do for this year as we flatten OpEx, as we drive our revenue growth, right? We've talked externally about sort of this 30% growth was our goal for the coming years. And as we look at gross margin improvement, when you put those building blocks together and you truly flatten OpEx and have targeted investment and careful diligence on all your spend, you really start to drive cash. You end the year with a cash number that allows you to move into 24 with the momentum to get to cashflow positivity, operating cashflow positivity in 25. It's really what those building blocks is. It's sort of how, how we get there. You know, we'll make targeted investments in, we'll continue to fund the growth in sales marketing. We've built a tremendous sales force and great products, which will drive that revenue growth. We, we have the ability to really focus on cost within cost of goods. As we've grown the company in the last two years since IPO, the focus naturally is on growing that revenue. And now we really have the ability to take costs out from a cost of goods perspective, drive that margin up. And then we have a good base of OPEX that we don't expect to grow. We'll be able to flatten that OPEX. And when you put those components together, you get to the cash number we think we need to hit and the cash that we have on hand to meet our near-term goals.
spk23: I mean, that was great.
spk07: Did you want to just clarify the financing potential or just?
spk09: I mean, like I said, right now we've got the cash on hand. We need it to execute against our near-term goals.
spk07: Okay. Okay. No, that was great. Thanks, Johnny. Just moving on to the industry, the company really. So you had great quarter. Like I said, the other spatial companies focused on transcriptomics did as well. They raised guidance. Are you seeing anything interesting in the funding environment or overall budget allocations given the number of all these capital equipment options right now? And then specifically, just kind of curious if you're seeing labs purchase a box with a focus on analyte or maybe some other metric. In other words, are you kind of like sort of on your own with spatial proteomics?
spk16: So let me take that last part first. The dynamics that we've spoken about, about, you know, a broadly growing spatial biology market, but still in terms of buying behavior, customer type, I think, and I suspect that our colleagues at Tenex and Nanostring would think similarly, that it's not really a head-to-head with Akoya. We're still in a market segment, Kyle, where we're really not running into those customers, They're field forced very much at all. I think those dynamics may start to change towards the latter part of this year as perhaps both of our portfolios pivot to include the other analyte. But I would harken back to Mason's question on how we think about that market opportunity for us. So even a slight amount of some moderate success in the genomics market for us would be, I think, significant upside for us. In terms of the funding environment, Kyle, we're not really seeing anything dramatic to the negative. I would say similar trends to what we talked about in Q1 in terms of diligence around capital purchases. You know, some reagent pull through resurgence in China, but not quite back yet.
spk07: Okay. Awesome. I mean, and that first part there, I mean, I have received some, you know, questions about that in the past. So there is some, you know, maybe misunderstanding of some of this stuff out there. So that's all good. Maybe just a quick one. I want to hop off after this. Any inbound interest or order funnel commentary for the discovery panels right now on the RNA side? We'd love to hear that because this is your first time doing the kind of standalone RNA.
spk16: Yeah. So the first launch of the discovery panels, at least that wasn't clear, Kyle, is protein. This is an immune cell. cell profiling panel launched at AACR. So a huge amount of interest at AACR for that component. And when you combine it with a lot of the other content, really along with Fusion 2.0, really central to driving up the Plex. But what I would also add, taking some liberties with your question, those discovery panels run on the cycler with the Fusion. By their name, the signature panels are really biomarker signatures. Those are designed to run on the HT. And we had a number of those launched in Q1, and there was a lot of inbound interest by our CRO and Biopharma's customers because the content there is so central and core to IO and oncology and checkpoint inhibitors and activated till status, et cetera. So those are really, those are of great interest as well, the signature panels on the HT and remembering that that for us in terms of top line, those really help our pull through on the HT because historically we've only sold the detection reagent component of that asset. So about 30 cents on the dollar. By selling these signature panels with that ready-made content for BioPharm and CRO partners, now we're getting sort of that realizing the full value because we're putting those panels together and getting the antibodies. So I appreciate you letting me take some liberties with the question. Hopefully that was clarifying.
spk06: Yeah, very thoughtful, Brian. Appreciate it. Thanks, guys.
spk24: Thank you. One moment as I prepare the next question. Our next question comes from David Westenberg from Piper Sandler.
spk25: Your line is now open.
spk11: Hey, guys. Thank you for taking the question. So I just want to ask about the RNA scope, the biotechnology deal. I believe it should be this quarter. I think it's dependent, if I'm not mistaken, on Fusion 2.0 release. Can you talk about maybe how much, correct me if I'm wrong, and then can you talk about the time elapse between Fusion 2.0 and the launch of the RNA scope as a reminder?
spk16: Yeah, so the 2.0 hardware and software upgrades, David, has all of the necessary components to run the RNA scope. So as we roll that out in the field and likely get pulled to do so by those groups interested in RNA scope, it's fully enabled with that upgrade.
spk11: Got it. Oh, so it would be the exact same time. It would be concurrently. It would be concurrently, yeah. Okay, perfect, perfect. Thank you very much. Gotcha. Then I want to pivot to something else. I think I saw a partnership or a new customer in Fulgen that's picking up your assay now. We cover them in profitability or running assays or building assays that are profitable is very central to the way they operate. Can you talk about either them specifically or how a diagnostics customer can really use your platform here to build new profitable assays? Thank you.
spk16: Yeah, so I won't talk about them specifically, although that is one of the great stories that I've ever learned as a businessman, how it kind of grew and what they've done there. So an incredible job by that team. But I'll speak more generally about to Fulgent and companies like those because what we're seeing, David, is we're seeing a really accelerating recognition in the true service opportunity, CRO opportunity, and translational and clinical need for multiplexing, period. We call it spatial biology, but the reality is in a CRO setting, this is multiplexing. And they're doing multiplexing on our platform because it's fluorescent. And they're doing it with fluorescence because that allows them scientifically, and I apologize for going in the weeds, to look at biomarkers that co-locate on a single cell. That capability to do clinical-grade multiplexing for markers like PD-1 and PD-1 and CD-8 and CD-4 and CD-20 that all co-locate, you need to have the technology that can ferret out those signals. And so what our customers, what our CRL customers like Fulgen and others are seeing is they're seeing demand from pharma. And they're seeing an opportunity to sell services for multiplex-based immunofluorescence, immunistic chemistry. And that's exactly what we want. That's why we built the panels. That's why we keep improving the HD system. That's why we did ABS, our CLIA lab, so we would have clinical grade protocols that we could then share with all these groups. So we have consistency of performance. So this is, and I really appreciate you asking the question, David. This is a really, really powerful dynamic where we're seeing CROs beginning to promote multiplexing on our platform as a solution. And that's the kind of flywheel effect that we hope for, plan for with the HT, with the signature panels, with the ABS methodologies, everything I just went through.
spk11: Thank you very much, Brian. We'll chat with you offline in an hour, a couple hours. Thank you. All right. Thank you, David.
spk24: Thank you. One moment as I prepare the next question. Our next question comes from Tejas Savant of Morgan Stanley.
spk04: Your line is now open. Hey, guys. This is Edmund. Thank you for taking my questions today.
spk05: Hey, I just wanted to double-check on something with the Fusion 2.0 rollout. You guys said that the instrument will meet the multi-carrier slide requirements upon the software upgrade. Would there be another catalyst later on this year to unlock the full throughput of that, or is that going to be available immediately, just like the RNA scope?
spk16: So, yeah, so the 2.0 is multi-slide. It's got all the components to enable RNA scopes. And then there's some software upgrades and data post-processing improvement. That's the biggest, largest set function for this year on the platform side. But what I would add, Edmund, is that additive and a driver over time is the launch of more and more of these discovery panels. Because what those do is they make it really easy for you to stitch together, you know, groups of 10 to 20. These are in modules. Immune profiling modules, immune activation modules, lymphocyte profiling modules. You stitch these things together and very quickly you build a 60, 70 plex versus you might have been averaging a 30 plex or so before. So the modules and the software partners help, I hope, convince our customers to take that multi-slide carrier and get full utilization of it. So it's sort of a flywheel effect, if that makes sense, Edmund.
spk17: Understood.
spk05: And then in regards to discovery panels having RNA capabilities by the second half of 23, will that simply be with the RNA scope? I think, if I'm not mistaken, that's around like a handful of plex. But what about your... internal 100 plex-ish panel. Is that going to be second half of this year as well, or is that the point?
spk16: Yeah, I appreciate the question. So, the current guidance that we've given is the 2.0 has everything needed to enable the RNA scope, and that's about up to a 12 plex. They're high plex, RNA scope, high plex, 12 plex. And then it is our own internal RNA that's higher plex, and then ultimately multi-omic that we've talked about for second half.
spk05: Okay, yeah, thank you. And then one final question on me in terms of your Enable Medicine partnership. Can you remind us how this differs from your collaborations you currently have with VisioPharm, PathAI, and Oracle? Should we just view this as another downstream analysis tool in the toolbox for researchers?
spk16: In short, yes. We're trying to give an array of offerings. that suit the needs, the different needs of each customer. And I will come back to Visioform. I'm sorry, Enable Medicine. But, you know, there's solutions like QPath. And that's freeware. That's free. And you can plug in. You can do R scripts. So that's a freeware. Oracle Bio is a group that, for example, can do really powerful bespoke-based biomarker discovery and analysis path ai has both a lab but also strong ai capabilities where they can take large-scale cohort studies and find the signatures themselves and then groups like vizio farm and indica labs they have huge install bases they've been in market for a long time real industry leaders and both do very well in biopharma enable medicine enable medicine is a cloud-based solution and that was really built initially to serve our discovery market segment that are doing real HyPlex studies. And as we noted in the opening comments, they've already analyzed over 20,000 samples on that platform. So it's been robustly tested and they rolled this out as a software as a service package, enabling our phenocyclic fusion customers to try it out initially in a very affordable manner. So it's a very scaled cloud-based solution. And they also, as a company, illustrated with the fact that they've done 20,000 samples, they have a real robust services lab using our platforms as well. So again, it's really about a continuum of offerings that meet the different needs of academia and industry alike.
spk05: Got it. That's super helpful. And just one final one from me. One of your competitors have mentioned offering onboard primary and secondary analysis to their instrument, and you've also mentioned adding that to your HT instruments as well. Is that something we should consider down the road as something you will do for your phenocyclic regions?
spk16: So, in short, we've already, we've done a lot of that already. I just, I think there's some components to structure out, and you're right. I think it's a standard that needs to take place. So, there's a compression approach. There's a compression that allows this to happen in a compute-friendly manner. So, first, when you compress that, data format, then the onboard, the cost of that onboard compute doesn't have to be exorbitant. And then once you have that onboard compute like we have with EHT, you can do a lot of that post-processing real time. Whether or not we roll that into the phenocycler fusion, it's not as pressing a need, that post-processing. The reason why it's so valuable on the HT is because you basically remove that post-processing. So the time from sample to answer for a clinical study, you take a big chunk off of that. So that's really about consistency and time to answer.
spk03: Got it. Thank you for the time today.
spk24: Thank you, Edmund. One moment as I prepare our next question. Our next question comes from Lucas Baranovsky of UBS. Your line is now open.
spk13: Hi, guys. This is Lucas on for John Sauerbeer here at UBS. A lot of my questions have been asked already, but I guess going back to the phenocode signature panels and the phenocode discovery panels, which of those two do you expect to drive more pull through in 2023?
spk16: That's a really good question, Lucas. I don't, it's like having me choose between my children. I don't think, I don't think any one of those is an outlier. The only thing I would add is that it's perhaps more about scheduling, schedule. So the phenocode signature panels, we launched three of the four in, in three of the four panels here in the first quarter. But the nature of the use of those is pharma will try those on a pilot study. analyze, and then scale. So it's a sort of bimodal adoption. The discovery panels are going to come out over time, and those are going to be more organic as they roll in. So while the adoption curves look different, sort of a gradual growth versus this bimodal pop in the discovery versus the signature, respectively, I think their contributions are going to be fairly equivalent in terms of added top-line revenue.
spk13: Thanks. That's really helpful. And then I guess more generally, looking at total revenue, can you talk a little bit about, you know, the pacing for the year and, you know, the biggest puts and takes we should be thinking about as we kind of forecast the next few quarters?
spk16: Yeah, I mean, I think as you look at our performance in, you know, look at sports sort of Q4 to Q1 and, you know, sort of the allocation of revenue across the categories, I think that's a decent starting point. I think what we expect over the coming quarters is that reagent growth to continue to go up a little bit more. So I think our Q4 contribution of reagents to the total will likely be more than Q1, for example, in terms of the absolute dollars. So I think that would be the loose guidance that we would give, and we can certainly dig a little bit more on the specific models as a follow-up. I don't know, John, you wanted to add anything to that?
spk09: No, I think naturally we certainly expect with the number of placements in the field as those all are live and continue to drive, pull through, it's a relatively step through the year to get to that Q4 exiting revenue.
spk14: Okay. Thank you very much. That's all I had. Thank you, Lucas.
spk25: Thank you for your questions. At this time, I would now like to turn it back to Brian McKelligan for closing remarks.
spk16: Well, listen, thanks. I don't have a lot to add. I think we covered a lot of the content. I just want to thank everybody for their time, their support, their questions. And, you know, again, we're really encouraged by our strong performance in this Q1 of this year, consistent with prior quarters. And we're going to continue this maintained, consistent, high growth performance. And we're really excited to capitalize off of all of our product opportunities. from instruments, reagents, to services, again, across this broad continuum of market segments. And I think that's, again, what's unique and powerful about Akoya is we have diversity of revenue, not just across product types and geographies, but also across market segments. And it's that market segment and being successful across all three of those, from discovery to translation to clinical, that gives us strong foundations, not just for growth this year, but going forward into the future. So with that, I appreciate everybody's time, and we look forward to talking again soon.
spk25: Thank you. Thank you for today's participation in today's conference. This does conclude the program.
spk24: You may now disconnect. All right. We'll jump on to our first callback.
spk23: All right. Thank you, Gerald. you Bye. Thank you.
spk25: Good day, and thank you for standing by. Welcome to the Akoya Biosciences first quarter 2023 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand it over to our first speaker.
spk26: Thank you, Operator, and thank you to everyone who is joining us today on this call. I'm Priyam Shah, Head of Investor Relations at Akoya Biosciences. On the call today, we have Brian McElligan, Chief Executive Officer, and Johnny Yak, our newly appointed Chief Financial Officer. Earlier today, ACOIA released financial results for the first quarter and did March 31st, 2023. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relates to expectations or predictions of future events, results, or performance are forward-looking statements. Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. For a list and description of the risks and uncertainties associated with the COIS business, please refer to the risks identified in our filings with the U.S. Securities and Exchange Commission, including in the risk factors section of our annual report on Form 10-K for the year ended December 31st, 2022, filed on March 6th, 2023, and subsequent filings of the SEC, including our quarterly report on Form 10-Q for the quarter ended March 31st, 2023, filed today, May 8th, 2023. We urge you to consider these factors, and you should be aware that these statements are considered estimates only and are not a guarantee of future performance. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, May 8th, 2023. ACOIA disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. The audio portion of this call will be archived on the investor section of our website later today under the heading events. And with that, I will now turn the call over to Brian.
spk16: Thank you, Prem, and good afternoon or evening to everyone. We appreciate you joining us today. On today's call, we will discuss our performance for the first quarter, review our product strategy, and give updates on the upcoming product launches. Johnny will then provide a more detailed look at our financials, business trends, and outlook. I'd like to start by extending a warm welcome to Johnny Eck, who joined Acquia's leadership team as Chief Financial Officer in March. Johnny brings more than 20 years of financial and operational leadership across the diagnostics and life sciences industries, including at leading companies like Affymetrix, Genmark, and most recently, Specific Diagnostics. Johnny succeeds Joe Driscoll following his retirement. Joe was an integral part of Acquia's success over the last four years. and guided the company through an incredible growth trajectory, including our IPO. He will be missed, and I wish him a wonderful and well-deserved retirement. Additionally, we announced the appointment of Jennifer Kamichai as our new general counsel. She will be a vital member of the executive leadership team and will oversee all the company legal activities. So let me move on briefly to summarize our performance in Q1. Akoya had a very strong start to 2023, highlighted by the placement of our 1000th instrument in the field in April. This was a major milestone for the company. We also reported record revenue of $21.4 million for the first quarter, a 27% growth over the prior year. Our continued robust growth is a byproduct of our leadership in spatial biology, delivering a portfolio of products and services spans the full continuum of market opportunities from early discovery to translational and ultimately the clinical markets. Now, this is an important and valuable differentiator for Akoya. That is, we're achieving success across a broad range of market segments with complete end-to-end solutions purpose-built to serve the unique needs of each customer type. This range and diversity of products provides the company with a strong foundation and the core fundamentals for both near-term and long-term sustained growth. A key demonstration of our current and predictor of our ongoing success is the continued and rapid growth of publications featuring ACOIA's platforms. As of March 31st, there are now 860 publications featuring our solutions, a 62% growth from the prior year period. Additional highlights for the quarter include $5.7 million in reagent revenue, a 27% sequential quarter-over-quarter growth, and the largest quarterly reagent revenue in ACOIA's history. We reported $5.9 million in service and other revenue, a 64% year-over-year growth driven by the continued success of our lab services business. Prior to reviewing our forthcoming strategic initiatives, I want to spend a minute to review and reiterate Akoya's multi-year strategy initiated following our IPO in April of 2021. Our primary goal was to establish Akoya as the market leader in spatial biology from discovery to diagnostics. Now, there's two phases to this strategy. The first phase was initiated following the IPO and lasted to the end of 2022 and included three distinct strategic objectives. First, following the IPO, we made immediate investments in R&D to develop and deliver a complete and industry-leading portfolio of instruments and solutions to serve the discovery, translational, and clinical markets. We expanded our SG&A organization to have the scale, the expertise, the processes, and the systems in place to immediately capitalize on these product launches to drive revenue growth. Third, we solidified the clinical readiness of our organization and our product portfolio to set the foundations to achieve our long-term goal of penetrating the large spatial biology clinical camp. And by all accounts, We successfully executed on this the first phase of our strategy. Specifically, we delivered solid revenue growth ahead of expectations every quarter since our IPO in April of 2021 through Q1 of this year. We successfully launched new products like Diffusion as key drivers of this growth. And we launched and expanded our lab services business and achieved CLIA certification culminating in our first companion diagnostic partnership. Our revenue performance, 1,000 instruments in the field, and nearly 900 publications are the most obvious metrics that highlight our solid R&D and commercial execution. And now in 2023, we are embarking on the second phase of this multi-year strategy to lead in spatial biology from discovery to diagnostic. And now underway, the objectives of this second phase include the following. First, with our organization now at a scale to deliver on our strategic priorities, we will focus on improving operational leverage by limiting and targeting our investments while also continuing to deliver robust top-line growth. Second, we're focusing our R&D initiatives on workflow improvements and reagent solutions that drive increases in consumable revenue and system pull-through. Over time, we expect that these high margin reagents will contribute a growing percentage of our total overall revenue, driving an increase in our gross margins. Third, we will continue to focus on advancing our clinical market development efforts, lab services, and advancing and expanding key partnerships like Akron and Agilent to begin to address the significant spatial clinical opportunity. The goal of this second phase of our strategy will be to deliver sustained high top-line growth with increasing margins, achieve cash flow positivity in 2025, and to expand on our success in the clinical market. So now let me walk through our product roadmap for this year with the goal of continued workflow simplification and consumable revenue growth. We have coordinated priorities for investments and improvements across reagents, instruments, and software. We expect that our expanded reagent menu with our Pheno code discovery and signature panels will drive an increase in system utilization, Plex, and pull-through. Our planned hardware upgrades on both the Pheno, Cycler, Fusion, and the HT will further simplify our workflows and also contributing to utilization and pull-through growth. And our expanding ecosystem of software partners will reduce our customers' time from data to answer. Let me talk in more detail in each of these, first starting with our reagent strategy. We are expanding our reagent menu this year with ready-made panels for both the phenocyclic diffusion for HyFlex Discovery and the PhenoImager HT for high-throughput translational studies. These biomarker panels fall under our PhenoCode reagent brand and include our PhenoCode Discovery panels for the phenocycler fusion and the PhenoCode Signature panels for the PhenoImager HT. The Discovery panels will have a rolling launch throughout 2023. The first panel, focused on immune profiling was launched at this year's AACR. The next three panels were launched throughout the second half of this year. These panels are designed in a modular fashion of 10 to 20 markers, providing our customers the ability to combine them while also including additional ACOIA catalog antibodies or their own as needed. For the translational clinical markets, we're launching five PhenoCode signature panels for the PhenoImager HT. The first three panels were launched in Q1, and the next two are due in the second half of this year. These panels were created for the rapidly advancing immuno-oncology therapy landscape that includes nearly 6,000 ongoing clinical trials. The signature panels enable fast and scalable assay to development and deployment, and accelerating utilization higher revenue per sample on our ht system with the launch of these high value reagent panels we're also making continued workflow improvements across all of our systems to simplify and accelerate our workflows as previously discussed the fusion 2.0 instrument field upgrade is planned for this the second quarter and will deliver an increase in throughput and workflow simplification for our customers. This upgrade includes a multi-slide carrier on the fusion for parallel processing of tissue samples, which effectively doubles the system throughput from approximately 10 samples per week to up to 20 or more samples per week. This upgrade also includes the necessary hardware and software components to support biotechnics R&A scope to be used on the phenocyclofusion. On the PhenoImager HT, we are continuing our efforts to simplify and streamline our informatic workflow and post-processing to a true clinical standard. In mid-2023, we plan to introduce further improvements to the HT that moves the post-processing and tissue analysis steps directly onto the HT for on-instrument real-time compute. The result will be a several-fold reduction in image post-processing and turnaround time. This upgrade supports our translational and clinical customers' demand for a rapid and standardized workflow to drive throughput and standardization. Expanding our content menu and streamlining our workflows are two out of the three necessary improvements to drive increased system use. continue to advance and improve our data analysis and software solutions is the final piece. As we have discussed, our software strategy is grounded in two assumptions that are absolutely proving true. First, the rapidly expanding spatial biology market is driving the introduction of many new powerful data analysis solutions from both industry and academia. Our customers benefit the most if we can partner with these groups to ensure compatibility with our platforms. Second, our resources are better spent enabling these partners versus building a single solution that must serve this broad range of customer needs. And to remind you, Akoya's platforms leverage an on-instrument image processing and file compression technology that reduces file sizes by 30-fold. from terabytes to gigabytes, into a standardized file format called QPTIF. Now, this novel and proprietary technology enables an ease of data transfer through this standardized format to help simplify and accelerate the development of third-party software solutions. At ACR, we announced the newest member of a software partner ecosystem, EnableMedicine. Enable is now commercializing a cloud platform specifically optimized for phenocycler data sets. To date, they have already established the platform's robustness, having analyzed over 20,000 samples on the Enable cloud platform. Available as a software as a solution package, it will accelerate the ability of Akoya's customers to go from data to cell phenotypes to insights in minutes or hours instead of days or weeks. In addition to this partnership, we have also partnered with other established industry leaders like Visioform, Indica Labs, Path AI, and Oracle Bio. We expect the continued growth of spatial biology will spur ongoing developments of additional software solutions for the discovery, translational, and clinical markets. In addition to the upstream discovery market, we continue to make great progress in the downstream translational and clinical diagnostic markets, leveraging the PhenoImager HT and our Advanced Biopharmaceutical Solutions CLIA Lab or AVS. Our partnership with Angeline has already generated meaningful customer engagements with top biopharmaceutical precision medicine groups, driving and expanding our AVS pipeline. In addition, Our agreement with Akravan Therapeutics to exclusively co-develop and commercialize a first-of-its-kind spatial signature companion diagnostics continues to advance. Akravan recently announced that it anticipates initial clinical data from the Phase II multicenter open-label trial in patients with platinum-resistant ovarian, endometrial, and urothelial cancer during the second half of 2023. Now, to review, we're focused on the following initiatives throughout the rest of 2023. First, continue to deliver new applications and drive further workflow and speed improvements to increase the reagent pull-through on the phenocycler fusion in the discovery market and the Pheno-Imager HT for the translational and clinical markets. Second, continue to partner with leading biopharma, medical centers, CROs, and diagnostic leaders to drive the adoption of the PhenoImager HT in the translational research and clinical diagnostic markets. Finally, with the support of our new and expanded leadership team, we will drive operational efficiencies and make limited and targeted investments going forward to achieve cash flow positivity in 2025. Now, with that, I will now turn the call over to Johnny to discuss our financial results. Johnny?
spk09: Thanks, Brian, for the kind introduction and warm welcome. It's a pleasure to be on this call today, and I look forward to working alongside Brian and the team in leading Akoya on the next phase of its journey. And I want to thank Joe for what has been a seamless transition, and I wish him all the best in his retirement. As Brian highlighted, total revenue for the first quarter of 2023 was $21.4 million. a 27% growth over the first quarter of 2022. Our robust year-over-year growth reflects a strong portfolio meeting the needs of a broad customer base across multiple research verticals and revenue categories. Product revenue, including instruments, reagents, and software, totaled $15.5 million for the first quarter, representing 17% growth over the prior year period. Instrument revenue was $9.6 million for the first quarter, representing 13% growth over the prior year period. We had another strong quarter with 58 total instruments sold, of which 19 were phenocyclers and 39 were from the PhenoImager portfolio. We ended the first quarter of 2023 with a total installed base of 992 instruments, which includes 273 phenocyclers and 719 phenol imagers. As Brian highlighted, in April, we celebrated an important milestone, shipping our 1,000th instrument. A total of 149 fusion instruments have shipped since the full commercial launch at the start of 2022, and we now have a total installed base of 128 for the combined phenocycler fusion system sold either directly as a combined system or as an upgrade to a standalone phenocycler instrument that previously utilized a third-party microscope. More than a year into the launch, the majority of the phenocyclers are being sold in combination with the fusion. As expected, we see the combination of the phenocycler and fusion driving increased reagent pull-through, and we expect this to continue to increase over the coming years with new product introductions, which Brian discussed as part of our product roadmap. Reagent revenue was $5.7 million for the first quarter of 2023, representing a 27% sequential growth over the fourth quarter of 2022. In this early part of 2023, we are seeing the efforts of our focus on driving reagent growth begin to show encouraging results. Our annualized pull-through per instrument in 2022 was in the low $30,000 range for both the phenocycler which was predominantly paired with third-party microscopes, and the phenol imager HT. The annualized first quarter reagent pull-through was in the mid-$30,000 range as more phenocyclers paired with fusion are up and running. We are targeting annual reagent revenue growth in the 40% range per year for the next several years as we expand our install base, realize pull-through expansion across this large install base, and as ongoing product launches hit a commercial stride. Service and other revenue totaled $5.9 million for the first quarter, an increase of 64% over the prior year period. Services have been a substantial growth segment for us over the past several quarters for a couple of reasons. Lab services revenue continues to grow as more pharma customers utilize our services to drive higher scale studies and our companion diagnostic deal with Akron Therapeutics continues to advance with the clinical trial underway. Gross profit was $12.3 million in the first quarter, representing 22% year-on-year growth, and gross margin was 57.4%, an increase from 56.8% in Q4 of 2022. As reagents become a bigger part of our revenue mix, And as we leverage our manufacturing investments to date, we will continue to expand our gross margin over time. Operating expenses for the quarter totaled $29.9 million as compared to $29.6 million in the fourth quarter of 2022. As Brian noted, we have now begun to leverage our cost structure to drive the business towards profitability and are planning a flattening of our operating spend throughout 2023 and into 2024. With historical investments in business expansion efforts since the IPO, we have developed products, built operating infrastructure, and streamlined commercial execution to drive top line growth with expanding operating leverage. Our plan for 2023 includes targeted investments in areas that will generate the highest returns as we work towards operating cash flow positivity in 2025. We ended the quarter with approximately $60 million of cash and cash equivalents and approximately $11 million in additional debt capacity. The first quarter of each fiscal year is typically our highest cash usage quarter as we make bonus and other similar annual payments. In addition, we have invested in higher inventory levels to continue to cushion against potential supply chain issues and offer a more expansive reagent menu. We expect to maintain robust top line growth throughout 2023 with reduced cash burn as we recognize operating leverage and flattened OPEX. Common shares outstanding and fully diluted shares including the impact of outstanding options and unvested restricted stock awards are 38.4 million as of March 31st, 2023. To summarize, We had another record quarter with $21.4 million in revenue, 27% growth over the prior year. We have a total installed base of 1,000 instruments as of April, the largest installed base in the spatial biology industry. We recorded our highest reagent revenue in ACOIA's history this quarter of $5.7 million, representing 27% sequential quarter-over-quarter growth driven by an expanding installed base and increasing pull-through on the phenocycler fusion. And finally, with an industry-leading volume of publication featuring ACOIA's platforms, now at 860 as of quarter end, representing a 62% year-over-year increase, we remain confident in our ability to deliver continued growth in 2023. Currently, we are reiterating our revenue guidance range of $95 to $98 million for 2023 as we continue to see tailwinds for our business and the spatial biology market. Now I'll turn it back over to Brian for closing remarks.
spk16: Thank you, Johnny. We're pleased to report a strong quarter and announce multiple exciting new developments across the portfolio. We're thankful for the hard work of our fellow dedicated Akoyans, as well as for the support of our customers and shareholders. Akoya remains very well positioned growth and we're excited about the opportunities that lie ahead as we deliver new spatial solutions from the discovery to the clinical markets. And at this point, we will turn the call over to the operator for questions.
spk25: Thank you. At this time, we will conduct a question and answer session. As a reminder to ask a question, you will need to press star 1 1 on your telephone and wait for your name to be announced. To withdraw your question, please press star 1 1 again Please stand by while we compile the Q&A roster.
spk24: Our first question comes from Tim Chang from Capital One.
spk25: Your line is now open.
spk02: Hey, thanks. Hey, Brian, you know, I listened to the Acrovan Therapeutics call that happened recently. You know, do you guys get significant milestone payments assuming that their clinical readouts in phase two, let's assume they are positive, would you guys get milestones from that?
spk16: We do. We get milestones without going into too much details, but we get milestones throughout the development phases and throughout the enrollment and clinical trial participation phases. as well as the readout on those. So it's a fairly typical, Tim, companion diagnostic agreement, but short answer is yes.
spk02: And maybe just a follow-up to that. I mean, obviously, there's a lot of precision medicine biotech companies out there. Yeah. You know, what do you think you need to do to get more of these types of deals where you can leverage your diagnostic capabilities on the clinical side?
spk16: Yeah, and maybe that's a great question, Tim, and I appreciate it. Maybe for the benefit of those that don't have the background, I maybe just back up a little bit. So we announced the partnership with Akravan last summer following their IND submission of their DNA damage repair compound, their phase two trial of the compound they inlicensed from Lilly. And that trial, that IND also included the CDX assay. that was run on our platform. And it's being run out of our CLIA lab. So the things that we need to accomplish, to your question directly, Tim, to secure more of these, is really, as we've spoken of prior, is really to continue, I'd say, shots on goal. It's opportunities in more and more clinical trials in a more clinical trials within our existing customer base and across multiple partners to increase the probability like we have with Acrovan where it becomes central to the actual clinical trial. And while we don't call out all of these details specifically as a separate line item, I think if you just look at our services line over the last five quarters or so, That's a pretty solid indication of us growing that business, but trying to be selective about it as well, Tim. The milestones for us to continue to march along, the CLIA lab was certainly an important milestone. This first companion diagnostic deal is a very important milestone because it gives our pharma partners the confidence and belief that we can handle the full submission process and end up having an improved system on market. And then finally, more recently, it's in January, the partnership with Agilent that provides our pharma partners the ability to have a full sort of clinical grade workflow and a partner between us and Agilent to know how to develop, run clinical studies, and commercially deploy a clinical trial. So there's a lot that goes into it, Tim, but it really is just a sort of a slow, steady grind to broaden the menu and number of opportunities we have within our clinical trial partner base.
spk02: Okay, great. No, that's very helpful, Brian. And, you know, best of luck getting more of these types of partnerships this year. Thank you.
spk25: Thank you. One moment as I prepare the queue for our next question.
spk24: Our next question comes from Mason Curricio of Stevens, Inc.
spk25: Your line is now open.
spk08: Hey, guys. Thanks for taking the questions. Sorry if I missed this. I'm jumping between a few calls here. But did you guys discuss revenue and growth by geography during the quarter? And if not, could you provide some color there?
spk16: Yeah, it's a good question. We did not. It was fairly balanced across all territories and across all product lines. There was no real outliers. Last year, there was some puts and takes across multiple categories that it wasn't relegated to us. But for us, it was fairly balanced across all categories. You know, China's starting to come back a little bit on the reagent side, not fully there. But all in all, there was no sort of real outliers.
spk08: Okay. Got it. Thanks. That's helpful. And then one more here on performance. I think when you guys were talking about the pull-through per instrument, you called out a range in the mid-40s over the next couple years.
spk00: Yeah.
spk08: Has that changed from any prior expectations or maybe any additional color there? I know that new platform owners tend to have lower pull through initially. So has your expectations changed around instrument placements? Has it gone up? Any additional detail there would be helpful.
spk16: No changes in instrument expectations or longer term pull through expectations. You know, we are beginning to realize, as Johnny alluded to in his talk track, we're starting to see the movement of that pull through on the phenocycler with many of those, you know, first half phenocycler effusion installs getting to full production. So kind of going from the low 30s to mid 30s. And I think Mason will continue, particularly on the phenocycler, will continue to see this sort of steady climb I'll pull through, you know, the overall reagent revenue of $5.7 million for this quarter was a pretty, pretty good step up from the 4.5 and Q4 last year. So no release in expectations. And I think all the, everything that we're doing on the product side is going to help drive that as I alluded to in my opening comments.
spk08: Perfect. Okay. And then one more, maybe high level question. I think historically you guys have talked about, somewhat of a bifurcation in the spatial market or discovery market. Protein labs, where you guys have historically focused, and then some genomic labs where competitors tend to play. But you've also pointed to this trend of multiomics and the expectation that the market is moving in that direction. So with that in mind, when you think about protein versus genomics labs, how do you think about which type of lab is is going to more rapidly adopt multi-omic solutions as these roll out or even use the analyte that they historically weren't broadly using in their research, whether it's RNA or protein?
spk16: Yeah, that's a great, great question. I'm going to rephrase it, Mason, to make sure I'm answering it correctly, which is you talked about proteomics and genomics customers. Where do we think multi-omics is going to resonate the most? To rephrase it simply, is that what you're asking? Yep, that's right. I actually think it's going to be more in the phenocycler fusion customer base because what they're looking at are they're looking at proteins as a really rich scaffold within which to understand cell-cell interactions as well as the key protein markers like the PD-1, PD-A1 checkpoints. And they're layering in RNA as an additive tool to look at secreted molecules and Chemokines, cytokines is an added question. So I think that kind of multi-omic customer is where your classic, you know, protein player is going to resonate the most. I think over time, I think you're going to see the genomics customers continue to focus more and more on genomics-based open-ended exploratory discovery questions, and that's the power of the transcript. So hopefully that answers your question. I think we're in that multiomics short story. Perfect. Yeah. Thanks, guys. Thanks, Mason.
spk24: Thank you. One moment as I prepare our next question. Our next question comes from Julia Quinn of JP Morgan.
spk25: Your line is now open.
spk20: Hi, good afternoon, guys. So I wanted to ask on the service revenue strength this quarter, could you give us a little more color on, you know, whether this is mainly driven by Akron scaling their studies or new biopharma customers? And then also two related follow-ups on that is, you know, are you seeing any changes in customer preference between service versus instrument, just in light of the macro environment we're in? And could you talk about the biopharma pipeline health and what's your latest outlook for the service business, given the strength? Thank you.
spk16: Yeah, so the growth in services is sort of a balanced contribution. Appreciate the question, Julia. A balanced contribution over the last five quarters or so from both of those sources. That is, both the AcroVon milestones and realizing revenue recognizing that as well as the growth in ABS now there is a component of that that also includes warranties and those that those sort of grow linearly with our install base and that's a component of that it's probably a minority that is and your second part of your question are we seeing preferences for services versus buying instrumentation there's nothing Julia I would point to that would significant that would signify a massive shift within how we go to the market with one very important asterisk which is we are seeing a lot more activity within our CEOs and core labs so it's not services by Akoya because the services that we're doing with ABS and Acrobon those are very targeted and that's a pretty rich pipeline of targeted translational clinical studies but more generally Julia I do think you're seeing in the external markets people shifting, and Able Medicine is one of those CROs that also has software, you know, core labs at many of our academic institutions. You're seeing these cores be a very, a really central component of not only how products go to market, but the first wave of adoption. That's one of the reasons why we think it's so important on the discovery side to focus on that throughput, that sample per unit time. Because then these core labs can actually have a business. If it's a sample every three to four days, they're going to have to charge a markup of thousands and thousands of dollars per sample. That's why throughput is so important on the discovery side. And then on the translational side, it's equally important to make sure that we have panels that are ready to go and are pre-automated so that these CROs can go out and market a full solution and not have to build panels anymore. So the service portion of the business that we're serving versus providing, I actually do think there's a trend towards that. It's a very important customer base. And then the biopharma pipeline, I think there's two ways to talk about it. As we look at our top pull-through accounts over the last few quarters, for both the phenocycler fusion as well as the HT, BioPharma are becoming an increasing percentage of those really high-performing accounts. So we're really seeing our platforms take off in BioPharma as a product sale, but also our BioPharma business, in terms of ABS that I already spoke to, that is pretty robust. But again, it's very targeted. So hopefully that answers your question, Julia.
spk20: Thank you very much.
spk24: Thank you. Thank you. One moment as I prepare our next question. Our next question comes from Mark Massario of BTIG.
spk25: Your line is now open.
spk22: Hey, guys. This is Vivian on for Mark. Thanks for taking the question. So could you update us on what the attachment rate for the genocycler fusion is for new customers as well as the existing installed base? I think it was hovering around 80% last quarter. And is it still your thinking that standalone phenocyclers will be in the minority going forward? Thanks.
spk16: Your numbers are correct, and so are your assumptions. And Johnny can correct me. But yeah, our attachment rate is above 80%. We think it's going to stay there. And there is still a... there's still a great opportunity for us to continue to upgrade existing phenocycler customers that are using third-party scopes. And as we roll out more and more product improvements to the phenocycler fusion, it's going to become sort of a growing attraction for those phenocycler customers to then upgrade to the fusion. Does that answer your question, Vivian?
spk22: Yes, perfect. Thanks, Brian. Just a follow-up, any preliminary thoughts on how the field upgrades for the Fusion 2.0 are progressing? And any initial feedback you've been receiving on the 2.0, I guess, in terms of the increase in throughput?
spk16: Yeah, those start next month. Okay. Yeah, so there's a lot of excitement and anticipation for those. Those will be rolling out next month. And, you know, the pace of those is sort of customer-dependent. in terms of are they mid-project, do they have to wait? So I don't think we're giving exact guidance on how many quarters it's going to take, but we expect that there'll be a lot of excitement for that upgrade because of the improvements, not just on the hardware side, the multi-slide carrier, but there's also some significant improvements on the software side in terms of workflow usability.
spk21: Okay, awesome. That's it for me. Thanks for taking the question.
spk16: Thank you.
spk24: Thank you. One moment as I prepare for the next question. Our next question comes from Kyle Mixon of Canaccord Genuinity.
spk25: Your line is now open.
spk07: Hey guys, thanks for taking the questions. Congrats on the quarter and thanks for providing the second phase strategic objectives. Those are actually pretty helpful. I think they're important components here that you kind of walk through the roadmap and so forth. But on the cash flow positivity by 2025, I just want to walk through some stuff there. So really, like, how do you get there? I think I heard, like, you guys talking about it. I think, John, you went into it in some detail. R&D efficiency is limited in targeted spending. Maybe you could just expand on it a little bit. I mean, it was good to hear that stuff. And then maybe the assumption is just, you know, P&L-wise, so flattening up X, top line growth, things like that. And importantly, if you guys could just talk through... if you're contemplating any additional financing, because based on the burn here, I mean, it kind of seems possible. So I just sort of appreciate that. Thanks.
spk09: Yeah, I'll take this one. Certainly. Hey, Kyle, thank you. So maybe it's helpful to kind of give building blocks, right? We think about, as you mentioned, we exit the quarter $60 million and change with $11 million and change as, you know, additional debt capacity. So starting the quarter with $70 million in capacity. And then we look at what we're going to do for this year as we flatten OpEx, as we drive our revenue growth, right? We've talked externally about sort of this 30% growth was our goal for the coming years. And as we look at gross margin improvement, when you put those building blocks together and you truly flatten OpEx and have targeted investment and careful diligence on all your spend, you really start to drive cash. You end the year with a cash number that allows you to move into 24 with the momentum that to get to cash flow positivity, operating cash flow positivity in 25. It's really what those building blocks is. It's sort of how we get there. You know, we'll make targeted investments and we'll continue to fund the growth in sales and marketing. We've built a tremendous sales force and great products, which will drive that revenue growth. We have the ability to really focus on cost within cost of goods as we've grown the company in the last two years since IPO, the focus naturally is on growing that revenue. And now we really have the ability to take costs out from a cost of goods perspective, drive that margin up. And then we have a good base of OPEX that we don't expect to grow. We'll be able to flatten that OPEX. And when you put those components together, you get to the cash number we think we need to hit and the cash that we have on hand to meet our near-term goals.
spk23: I mean, that was great. Did you want to just clarify the financing potential or...
spk09: I mean, like I said, right now we've got the cash on hand. We need it to execute against our near-term goals.
spk07: Okay. Okay. No, that was great. Thanks, Johnny. Just moving on to the industry, the company really. So you had great quarter. Like I said, the other spatial companies focused on transcriptomics did as well. They raised guidance. Are you seeing anything interesting in the funding environment or overall budget allocations given the number of all these capital equipment options right now? And then specifically, just kind of curious if you're seeing labs purchase a box with a focus on analyte or maybe some other metric. In other words, are you kind of like sort of on your own with spatial proteomics?
spk16: So let me take that last part first. The dynamics that we've spoken about, about, you know, a broadly growing spatial biology market, but still in terms of buying behavior, customer type, I think, and I suspect that our colleagues at Tenex and Anestring would think similarly, that it's not really a head-to-head with Akoya. We're still in a market segment, Kyle, where we're really not running into those customers they're field-forced very much at all. I think those dynamics may start to change towards the latter part of this year as perhaps both of our portfolios pivot to include the other analyte. But I would harken back to Mason's question on how we think about that market opportunity for us. So even a slight amount of some moderate success in the genomics market for us would be, I think, significant upside for us. In terms of the funding environment, Kyle, we're not really seeing anything dramatic to the negative. I would say similar trends to what we talked about in Q1 in terms of diligence around capital purchases. You know, some reagent pull through resurgence in China, but not quite back yet.
spk07: Okay, awesome. I mean, and that first part there, I mean, I have received some, you know, questions about that in the past. So there is some, you know, maybe misunderstanding of some of this stuff out there. So that's all good. Maybe just a quick one. I want to hop off after this. Any inbound interest or order funnel commentary for the discovery panels right now on the RNA side? I would love to hear that because this is your first time doing the kind of standalone RNA.
spk16: Yeah. So the first launch of the discovery panels, at least that wasn't clear, Kyle, is protein. This is an immune cell. cell profiling panel launched at AACR. So a huge amount of interest at AACR for that component. And when you combine it with a lot of the other content, really along with Fusion 2.0, really central to driving up the Plex. But what I would also add, taking some liberties with your question, those discovery panels run on the cycler, right, with the Fusion. By their name, the signature panels are really biomarker signatures. those are designed to run on the HT. And we had a number of those launched in Q1, and there was a lot of inbound interest by our CRO and Biopharma's customers because the content there is so central and core to IO and oncology and checkpoint inhibitors and activated till status, et cetera. So those are really, those are of great interest as well, the signature panels on the HT and remembering that that for us in terms of top line, those really help our pull through on the HT because historically we've only sold the detection reagent component of that asset. So about 30 cents on the dollar. By selling these signature panels with that ready-made content for BioPharm and CRO partners, now we're getting sort of that realizing the full value because we're putting those panels together and getting the antibodies. So I appreciate you letting me take some liberties with the question. Hopefully that was clarifying.
spk06: Yeah, very thoughtful, Brian. Appreciate it. Thanks, guys.
spk24: Thank you. One moment as I prepare the next question. Our next question comes from David Westenberg from Piper Sandler.
spk25: Your line is now open.
spk11: Hey, guys. Thank you for taking the question. So I just want to ask about the RNA scope, the biotechnology deal. I believe it should be this quarter. I think it's dependent, if I'm not mistaken, on Fusion 2.0 release. Can you talk about maybe how much, correct me if I'm wrong, and then can you talk about the time elapse between Fusion 2.0 and the launch of the RNA scope as a reminder?
spk16: Yeah, so the 2.0 hardware and software upgrades David, has all of the necessary components to run the RNA scope. So as we roll that out in the field and, you know, likely get pulled to do so by those groups interested in RNA scope, it's fully enabled with that upgrade.
spk11: Got it. Oh, so it would be the exact same time. It would be concurrently. It would be concurrent, yeah. Okay, perfect, perfect. Thank you very much. Gotcha. Then I want to pivot to something else. I think I saw a partnership or a new customer in Fulgen that's picking up your assay now. We cover them in profitability or running assays or building assays that are profitable is very central to the way they operate. Can you talk about either them specifically or how a diagnostics customer can really use your platform here to build new profitable assays? Thank you.
spk16: Yeah, so I won't talk about them specifically, although that is one of the great stories that I've ever learned as a businessman, how it kind of grew and what they've done there. So an incredible job by that team. But I'll speak more generally about to Fulgent and companies like those because what we're seeing, David, is we're seeing a really accelerating recognition in the true service opportunity, CRO opportunity, and translational and clinical need for multiplexing, period. We call it spatial biology, but the reality is in a CRO setting, this is multiplexing. And they're doing multiplexing on our platform because it's fluorescent. And they're doing it with fluorescence because that allows them scientifically, and I apologize for going in the weeds, to look at biomarkers that co-locate on a single cell. That capability to do clinical-grade multiplexing for markers like PD-1 and PD-1 and CD-8 and CD-4 and CD-20 that all co-locate, you need to have the technology that can ferret out those signals. And so what our customers, what our CRO customers like Bulgin and others are seeing is they're seeing demand from pharma. And they're seeing an opportunity to sell services for multiplex-based immunofluorescence, immunohistochemistry. And that's exactly what we want. That's why we built the panels. That's why we keep improving the HT system. That's why we did ABS, our CLIA lab, so we would have clinical grade protocols that we could then share with all these groups. So we have consistency of performance. So this is, and I really appreciate you asking the question, David. This is a really, really powerful dynamic where we're seeing CROs beginning to promote multiplexing on our platform as a solution. And that's the kind of flywheel effect that we hope for, plan for with the HT, with the signature panels, with the ABS methodologies, everything I just went through.
spk11: Thank you very much, Brian. We'll chat with you offline in an hour, a couple hours. Thank you. All right. Thank you, David.
spk24: Thank you. One moment as I prepare the next question. Our next question comes from Tejas Savant of Morgan Stanley.
spk04: Your line is now open. Hey, guys. This is Edmund.
spk05: Thank you for taking my questions today. Hey, I just wanted to double-check on something with the Fusion 2.0 rollout. You guys said that the instrument will meet the multi-carrier slide requirements upon the software upgrade. Would there be another catalyst later on this year to unlock the full throughput of that, or is that going to be available immediately, just like the RNA scope?
spk16: So, yeah, so the 2.0 is multi-slide. It's got all the components to enable RNA scopes. And then there's some software upgrades and data post-processing improvement. That's the biggest, largest set function for this year on the platform side. But what I would add, Edmund, is that additive and a driver over time is the launch of more and more of these discovery panels. Because what those do is they make it really easy for you to stitch together, you know, groups of 10 to 20. These are in modules. Immune profiling modules, immune activation modules, lymphocyte profiling modules. You stitch these things together and very quickly you build a 60, 70 plex versus you might have been averaging a 30 plex or so before. So the modules and the software partners help, I hope, convince our customers to take that multi-slide carrier and get full utilization of it. So it's sort of a flywheel effect, if that makes sense, Edmund.
spk17: Understood.
spk05: And then in regards to discovery panels having RNA capabilities by the second half of 23, will that simply be with the RNA scope? I think, if I'm not mistaken, that's around like a handful of plex. But what about your... internal 100 plex-ish panel. Is that going to be the second half of this year as well?
spk16: Yeah, I appreciate the question. So the current guidance that we've given is the 2.0 has everything needed to enable the RNA scope, and that's about up to a 12 plex. They're high plex, RNA scope, high plex, 12 plex. And then it is our own internal RNA that's higher plex, and then ultimately multi-omic that we've talked about for second half. Okay, yeah, thank you.
spk05: And then one final question on me in terms of your Enable Medicine partnership. Can you remind us how this differs from your collaborations you currently have with VisioPharm, PathAI, and Oracle? Should we just view this as another downstream analysis tool in the toolbox for researchers?
spk16: In short, yes. We're trying to give an array of offerings. um, that, that suit the needs, the different needs of each customer. And I will come back to Visio farm. I'm sorry, enable medicine, but you know, there's, there's, there's solutions like QPAP and that's freeware that's free and you can plug in, you can do our scripts. Um, so that, that's a, that's a, that's a freeware Oracle bio is, is a group that for example, can, can do really powerful, um, bespoke-based biomarker discovery and analysis. PathAI has both a lab but also strong AI capabilities where they can take large-scale cohort studies and find the signatures themselves. And then groups like VisioPharm and Indica Labs, they have huge install bases. They've been in the market for a long time, real industry leaders, and both do very well in biopharma. Enable Medicine is a cloud-based solution. And that was really built initially to serve our discovery market segment that are doing real HyPlex studies. And as we noted in the opening comments, they've already analyzed over 20,000 samples on that platform. So it's been robustly tested. And they've rolled this out as a software as a service package, enabling our phenocyclic fusion customers to try it out initially in a very affordable manner. So it's a very scaled cloud-based solution. And they also, as a company, illustrative of the fact that they've done 20,000 samples, they have a real robust services lab using our platforms as well. So again, it's really about a continuum of offerings that meet the different needs of academia and industry alike.
spk05: Got it. That's super helpful. And just one final one from me. One of your competitors have mentioned offering onboard primary and secondary analysis to their instrument. And you've also mentioned adding that to your HT instruments as well. Is that something we should consider down the road as something you will do for your phenocyclic fusions?
spk16: So, in short, we've already, we've done a lot of that already. I just, I think there's some components to structure out. And you're right. I think it's a standard that needs to take place. So, there's a compression approach. There's a compression that allows this to happen in a compute-friendly manner. So first, when you compress that data format, then the onboard, the cost of that onboard compute doesn't have to be exorbitant. And then once you have that onboard compute like we have with EHT, you can do a lot of that post-processing real time. Whether or not we roll that into the phenocycler fusion, it's not as pressing a need that post-processing. The reason why it's so valuable on the HT is because you basically remove that post-processing, so the time from sample to answer for a clinical study, you take a big chunk off of that. So that's really about consistency and time to answer.
spk03: Got it. Thank you for the time today.
spk24: Thank you, Edmund. One moment as I prepare our next question. Our next question comes from Lucas Baranowski of UBS.
spk25: Your line is now open. Hi, guys.
spk13: This is Lucas on for John Sauerbeer here at UBS. A lot of my questions have been asked already, but I guess going back to the phenocode signature panels and the phenocode discovery panels, which of those two do you expect to drive more pull through in 2023?
spk16: That's a really good question, Lucas. I don't, it's like having me choose between my children. I don't think, I don't think any one of those is an outlier. The only thing I would add is that it's perhaps more about scheduling, schedule. So the PHNA code signature panels, we launched three of the four in, in three of the four panels here in the first quarter. But the nature of the use of those is pharma will try those on a pilot study analyze, and then scale. So it's a sort of bimodal adoption. The discovery panels are going to come out over time, and those are going to be more organic as they roll in. So while the adoption curves look different, sort of a gradual growth versus this bimodal pop in the discovery versus the signature, respectively, I think their contributions are going to be fairly equivalent in terms of added top-line revenue.
spk13: Thanks, that's really helpful. And then I guess more generally, looking at total revenue, can you talk a little bit about, you know, the pacing for the year and, you know, the biggest puts and takes we should be thinking about as we kind of forecast the next few quarters?
spk16: Yeah, I mean, I think as you look at our performance in, you know, look at sports sort of Q4 to Q1 and, you know, sort of the allocation of revenue across the categories, I think that's a decent starting point. I think what we expect over the coming quarters is that reagent growth to continue to go up a little bit more. So I think our Q4 contribution of reagents to the total will likely be more than Q1, for example, in terms of the absolute dollars. So I think that would be the loose guidance that we would give, and we can certainly dig a little bit more on the specific models as a follow-up. I don't know, John, you wanted to add anything to that?
spk09: No, I think naturally we certainly expect with the number of placements in the field as those all are live and continue to drive pull through, it's a relatively step through the year to get to that Q4 exiting revenue.
spk14: Okay. Thank you very much. That's all I had. Thank you, Lucas.
spk25: Thank you for your questions. At this time, I would now like to turn it back to Brian McKelligan for closing remarks.
spk16: Well, listen, thanks. I don't have a lot to add. I think we covered a lot of the content. I just want to thank everybody for their time, their support, their questions. And, you know, again, we're really encouraged by our strong performance in this Q1 of this year, consistent with prior quarters. And we're going to continue this maintained, consistent, high growth performance. And we're really excited to capitalize off of all of our product opportunities. from instruments to reagents to services, again, across this broad continuum of market segments. And I think that's, again, what's unique and powerful about Akoya is we have diversity of revenue, not just across product types and geographies, but also across market segments. And it's that market segment and being successful across all three of those, from discovery to translation to clinical, that gives us strong foundations, not just for growth this year, but going forward into the future. So with that, I appreciate everybody's time and we look forward to talking again soon.
spk25: Thank you. Thank you for today's participation in today's conference. This does conclude the program. You may now disconnect.
Disclaimer